Investigational drug · Phase 2
STC-1010
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "STC-1010"
First trial start
2025
Jun 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STC-1010", any sponsor or status.
Conditions studied
As listed on its trial records.
- Unresectable Metastatic Colorectal Cancer
- Unresectable Locally Advanced Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "STC-1010" as an intervention, largest first.
Brenus PharmaIndustry
NCT06934538 · 90 participants (planned) · Start Jun 17, 2025 · Primary completion Jun 2028
Drug: STC-1010 + IS regimen + SOC therapy · For: Unresectable Metastatic Colorectal Cancer; Unresectable Locally Advanced Colorectal Cancer
Sites: Baltimore, Maryland; Brussels, Belgium; Bordeaux, France · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Unresectable Metastatic Colorectal Cancer
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- folinic acidPhase 34 trials
Astellas · Unresectable Metastatic Colorectal Cancer, Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.